MENLO PARK, CA & NEW YORK – (BUSINESS WIRE) – January 10, 2022–
KKR, a leading global investment firm, today announced the final closing of KKR Health Care Strategic Growth Fund II (“HCSG II” or the “Fund”), a dedicated $ 4.0 billion fund. to growth equity investment opportunities in the healthcare sector, primarily in North America and Europe.
HCSG II is the successor fund to the KKR Health Care Strategic Growth Fund (“HCSG I”), the first private equity vehicle dedicated to the growth of KKR healthcare, which closed definitively in November 2017 with capital commitments of $ 1.45 billion. Similar to its predecessor fund, HCSG II will aim to generate strong returns for clients by investing in innovative healthcare companies with proven products and services that are looking for a partner to market and develop. With a diversified portfolio approach, HCSG II will focus on the sub-sectors of biopharmaceuticals, medical devices, healthcare services, life science tools / diagnostics and information technology in the field. of health.
“Now more than ever, there is a significant demand both for innovative products and services in the healthcare industry and for an experienced and flexible capital partner to invest in their growth and extend their reach,” said said Ali Satvat, partner, global head of health. Care Strategic Growth and Co-Head of Healthcare Private Equity Americas at KKR. “Building on the strong momentum and tangible results we have achieved so far with the HCSG I, we look forward to continuing to partner with the best healthcare companies to bring these much-needed products and services to market for the benefit of patients around the world while delivering strong returns to our investors.
The HCSG II has received strong support from a diverse group of new and existing investors globally, including public pension plans, sovereign wealth funds, insurance companies, financial institutions, endowments , private wealth and financial technology platforms, family offices and high net worth individuals. investors. KKR will invest approximately $ 500 million of capital in the Fund alongside these investors through the Company’s balance sheet, affiliates and employee commitments.
“We are delighted to have the support of this diverse group of investors who share our passion for the opportunities we see in this growing market,” said Alisa Amarosa Wood, Partner and Group Head of Private Markets Strategies at KKR. “At nearly three times the size of its predecessor, HCSG II not only speaks of the attractive investment opportunities that we see, but also demonstrates the strength of our healthcare investment team, our strategy of strategic growth in healthcare. healthcare and our strong investment performance for Date. “
KKR has established a solid track record of supporting businesses across the healthcare ecosystem, having invested approximately $ 18 billion in the sector since 2004. KKR’s healthcare team now numbers nearly 35 dedicated investment professionals around the world. In addition to providing capital, the firm helps businesses grow through its industry experience and connections, operational expertise, global infrastructure and the resources of over 100 portfolio companies around the world. In 2021, KKR made a number of new investments as part of its strategic healthcare growth initiatives, including Argenta, Nordic Bioscience, Sapphiros, Geode Health and Cordis.
KKR is a leading global investment firm providing alternative asset management, capital markets and insurance solutions. KKR aims to generate attractive returns on investment by following a patient and disciplined approach to investing, employing world-class people and supporting the growth of its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer pension, life and reinsurance products under the leadership of The Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For more information on KKR & Co. Inc. (NYSE: KKR), please visit the KKR website at www.kkr.com and on Twitter @ KKR — Co.
See the source version on businesswire.com: https://www.businesswire.com/news/home/2020110005267/en/
Cara Major or Julia Kosygina
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK
INDUSTRY KEYWORD: MANAGE CARE BANKS PROFESSIONAL SERVICES PHARMACEUTICAL MEDICAL DEVICES HPITAL SURGERY INSURANCE BIOTECHNOLOGY MEDICAL SUPPLIES HEALTH FINANCING
SOURCE: KKR & Co. Inc.
Copyright Business Wire 2022.
PUB: 10/01/2022 07: 00 / DISC: 10/01/2022 07:02
Copyright Business Wire 2022.